Circumvent the Tariff challenges with an agile supply chain Consulting
Supply Chain Ecosystem Analysis now part of DBMR Reports
Global Veterinary Dermatology Drugs Market
Market Size in USD Billion
CAGR :
%
USD
4.79 Billion
USD
15.71 Billion
2024
2032
Forecast Period
2025 –2032
Market Size(Base Year)
USD
4.79 Billion
Market Size (Forecast Year)
USD
15.71 Billion
CAGR
%
Major Markets Players
Elanco
Merck & Co. Inc.
Virbac
Zoetis Services LLC
Boehringer Ingelheim International GmbH
Global Veterinary Dermatology Drugs Market Segmentation, By Animal (Companion Animal and Livestock Animal), Route of administration (Topical, Injectable, and Oral), Indication (Parasitic Infections, Allergic Infections, and Other Indications), Distribution Channel (Retail, Hospital Pharmacies, and E-commerce) - Industry Trends and Forecast to 2032
The global veterinary dermatology drugs market size was valued at USD 4.79 billion in 2024 and is expected to reach USD 15.71 billion by 2032,at a CAGR of 16.02% during the forecast period
This growth is driven by factors such as the increasing prevalence of skin diseases in animals and rising pet ownership, coupled with growing awareness of animal health and veterinary care
Veterinary Dermatology Drugs Market Analysis
Veterinary dermatology drugs are essential for treating a range of skin conditions in animals, including allergies, infections, parasitic infestations, and autoimmune disorders, ensuring better quality of life and health outcomes for pets and livestock
The market is driven by rising pet ownership, increasing awareness of animal health, and the growing incidence of dermatological conditions among companion animals
North America is expected to dominate the veterinary dermatology drugs market with a market share of 31.5%, due to high pet ownership rates, robust veterinary healthcare infrastructure, and growing demand for premium animal care products
Asia-Pacific is expected to be the fastest growing region in the veterinary dermatology drugs market with a market share of 25.5%, during the forecast period due to increasing pet adoption, rising awareness of animal health, and improving access to veterinary care
Companion animal segment is expected to dominate the market with a market share of 66.5% due to its rising pet adoption rates, increased spending on pet healthcare, and growing awareness of skin-related conditions in pets
Report Scope and Veterinary Dermatology Drugs Market Segmentation
Attributes
Veterinary Dermatology Drugs Key Market Insights
Segments Covered
By Animal: Companion Animal and Livestock Animal
By Route of administration: Topical, Injectable, and Oral
By Indication: Parasitic Infections, Allergic Infections, and Other Indications
By Distribution Channel: Retail, Hospital Pharmacies, and E-commerce
Innovation in Biologics and Precision Medicine for Dermatological Treatments
Rising demand for novel biologics and targeted therapies for chronic skin conditions in pets
Value Added Data Infosets
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include import export analysis, production capacity overview, production consumption analysis, price trend analysis, climate change scenario, supply chain analysis, value chain analysis, raw material/consumables overview, vendor selection criteria, PESTLE Analysis, Porter Analysis, and regulatory framework.
Veterinary Dermatology Drugs Market Trends
“Rise in Targeted Therapies and Innovative Drug Delivery Systems for Animal Skin Disorders”
A key trend in the veterinary dermatology drugs market is the growing development of targeted therapies and advanced drug delivery systems designed to enhance treatment efficacy and reduce side effects
These innovations include monoclonal antibodies and sustained-release formulations, which provide longer-lasting relief and reduce the need for frequent dosing
For instance, treatments such as lokivetmab (a monoclonal antibody targeting canine atopic dermatitis) offer targeted action against specific allergens, improving symptom control with minimal systemic impact
These advancements are improving treatment compliance, enhancing quality of life for animals, and expanding the therapeutic options available to veterinarians, thereby fueling market growth
Veterinary Dermatology Drugs Market Dynamics
Driver
“Rising Pet Ownership and Increasing Prevalence of Skin Disorders”
The growing global pet population, coupled with rising awareness about animal health and wellness, is significantly boosting the demand for veterinary dermatology drugs
Skin conditions such as atopic dermatitis, flea allergy dermatitis, and bacterial or fungal infections are increasingly common among companion animals, particularly dogs and cats, prompting more frequent veterinary visits and treatments
Pet owners are becoming more proactive in seeking specialized dermatological care to improve their pets’ comfort and quality of life, driving the market for targeted and effective dermatology medications
For instance,
In 2023, according to the American Pet Products Association (APPA), approximately 66% of U.S. households (equating to about 86.9 million homes) own a pet, and dermatological conditions are among the top reasons for veterinary consultations
As skin disorders become more prevalent and pet owners increasingly seek professional care, the demand for veterinary dermatology drugs is expected to rise steadily
Opportunity
“Innovation in Biologics and Precision Medicine for Dermatological Treatments”
Advancements in biologics and precision medicine are opening new avenues in veterinary dermatology, offering targeted treatments tailored to individual animals based on genetic and immunologic profiles
Biologics, such as monoclonal antibodies, provide precise action against specific disease pathways, reducing side effects and improving therapeutic outcomes for chronic skin conditions such as atopic dermatitis
In addition, innovations in diagnostic tools and personalized treatment plans are allowing veterinarians to accurately identify dermatological issues and customize therapies for enhanced effectiveness
For instance,
In October 2023, Zoetis reported growing success with its biologic therapy, Cytopoint, which uses a monoclonal antibody to target interleukin-31 (IL-31), a key cytokine involved in canine atopic dermatitis. The product provides long-lasting relief with a single injection, improving pet and owner satisfaction
As biologics and personalized approaches gain traction, they offer a significant opportunity to revolutionize veterinary dermatology care, enhance treatment precision, and expand the market
Restraint/Challenge
“High Cost of Advanced Therapies and Limited Access to Specialized Care”
The high cost of advanced veterinary dermatology drugs, especially biologics and specialty formulations, presents a major challenge, limiting their adoption among pet owners with budget constraints and in regions with underdeveloped veterinary infrastructure
Treatments such as monoclonal antibodies and targeted immunotherapies often come with premium pricing, which may not be affordable for all pet owners, especially when long-term or repeated dosing is required
In addition, access to veterinary dermatology specialists is limited in many rural or low-income areas, resulting in delayed diagnosis and suboptimal treatment outcomes for affected animals
For instance,
In July 2023, a report by the American Veterinary Medical Association (AVMA) highlighted the shortage of board-certified veterinary dermatologists in the U.S., with most specialists concentrated in urban centers. This geographic disparity, combined with the high cost of advanced treatments, limits care accessibility for many pets’ owner
Consequently, the limited affordability and accessibility of specialized dermatological care can hinder market growth, especially in emerging economies and underserved communities
Veterinary Dermatology Drugs Market Scope
The market is segmented on the basis of animal, route of administration, indication, and distribution channel
Segmentation
Sub-Segmentation
By Animal
Companion Animal
Livestock Animal
By Route of administration
Topical
Injectable
Oral
By Indication
Parasitic Infections
Allergic Infections
Other Indications
By Distribution Channel
Retail
Hospital Pharmacies
E-commerce
In 2025, the companion animal is projected to dominate the market with a largest share in animal segment
The companion animal segment is expected to dominate the veterinary dermatology drugs market with the largest share of 66.5% in 2025due to its rising pet adoption rates, increased spending on pet healthcare, and growing awareness of skin-related conditions in pets. The emotional bond between pet owners and their animals also drives demand for effective dermatological treatments. In addition, advancements in diagnostic capabilities and treatment options further support market growth in this segment.
The oral is expected to account for the largest share during the forecast period route of administration market
In 2025, the oral segment is expected to dominate the market with the largest market share of 46.5% due to its ease of administration, better compliance among pet owners, and broad availability of formulations. Oral drugs are often more cost-effective and convenient for long-term treatment of chronic dermatological conditions. In addition, advancements in palatable drug formulations enhance acceptance among animals, further boosting segment growth.
“North America Holds the Largest Share in the Veterinary Dermatology Drugs Market”
North America dominates the veterinary dermatology drugs market with a market share of estimated 31.5%, driven by high pet ownership rates, robust veterinary healthcare infrastructure, and growing demand for premium animal care products
U.S. holds a market share of 85.5%, due to the high prevalence of dermatological conditions in companion animals, increasing awareness among pet owners, and strong presence of leading pharmaceutical companies
The favourable regulatory policies, widespread availability of advanced treatments such as biologics, and increasing spending on pet healthcare continue to support market dominance
In addition, the rising trend of humanization of pets and growing investments in R&D for innovative dermatology solutions fuel the expansion of the veterinary dermatology drugs market across the region
“Asia-Pacific is Projected to Register the Highest CAGR in the Veterinary Dermatology Drugs Market”
Asia-Pacific is expected to witness the highest growth rate in the veterinary dermatology drugs market with a market share of 25.5%, driven by increasing pet adoption, rising awareness of animal health, and improving access to veterinary care
Countries such as China, India, and South Korea are emerging as significant markets due to the expanding middle-class population, growing disposable incomes, and increased focus on pet wellness
Japan remains a key player in the region, supported by its advanced veterinary services and growing demand for dermatological treatments for companion animals
India is projected to register the highest CAGR of 15.1% in the veterinary dermatology drugs market, driven by rapid urbanization, increasing veterinary infrastructure, and rising incidence of skin-related disorders in pets
Veterinary Dermatology Drugs Market Share
The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.
The Major Market Leaders Operating in the Market Are:
Latest Developments in Global Veterinary Dermatology Drugs Market
In October 2024, Animal Dermatology Group, Inc. expanded its network by acquiring four dermatology specialty practices: Long Green Animal Dermatology, Nashville Veterinary Dermatology, Animal Dermatology & Allergy, and Dermatology & Allergy Clinic for Animals. This strategic move aims to enhance the company's presence in veterinary dermatology services
In October 2024, Elanco Animal Health received FDA approval for Credelio Quattro, a monthly chewable tablet for dogs aged eight weeks and older. This oral medication treats and prevents infestations of fleas, ticks, roundworms, hookworms, and tapeworms, and also prevents heartworm disease. Credelio Quattro is expected to be launched in the first quarter of 2025
In September 2024, the U.S. FDA approved Zenrelia (ilunocitinib), a once-daily oral Janus kinase (JAK) inhibitor developed by Elanco Animal Health. This medication is indicated for controlling pruritus associated with allergic dermatitis and atopic dermatitis in dogs aged 12 months and older. Zenrelia offers a targeted approach to managing chronic skin conditions in canine
In April 2024, the European Medicines Agency approved Lotimax, a chewable tablet containing lotilaner, for the treatment of flea, tick, and mite infestations in dogs. Lotimax is also indicated for treating demodicosis (caused by Demodex canis), providing a broad-spectrum solution for common parasitic skin conditions in canines
In March 2024, the FDA approved Duotic, a combination of terbinafine (antifungal) and betamethasone acetate (glucocorticosteroid), for the treatment of otitis externa (ear infections) caused by yeast (Malassezia pachydermatis) in dogs. Duotic is notable for being the first FDA-approved veterinary otic medication targeting yeast-only infections without containing antibiotics
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
Interactive Data Analysis Dashboard
Company Analysis Dashboard for high growth potential opportunities
Research Analyst Access for customization & queries
Competitor Analysis with Interactive dashboard
Latest News, Updates & Trend analysis
Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Customization Available
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
Claudio Rondena
Group Business Development & Strategic Marketing Director, C.O.C Farmaceutici SRL
"This morning we were involved in the first part, the data presentation of MKT analysis, selected abstract from your work. The board team was really impressed and very appreciated, as well."
David Manning - Thermo Fisher Scientific
Director, Global Strategic Accounts,
Dear Ricky, I want to thank you for the excellent market analysis (LIMS INSTALLED BASE DATA) that you and your team delivered, especially end of year on short notice.
Sachin and Shraddha captured the requirements, determined their path forward and executed quickly.
You, Sachin and Shraddha have been a pleasure to work with – very responsive, professional and thorough.
Your work is much appreciated.
Manager - Market Analytics,
Uriah D. Avila - Zeus Polymer Solutions
Thank you for all the assistance and the level of detail in the market report. We are very pleased with the results and the customization. We would like to continue to do business.
Business Development Manager,
(Pharmaceuticals Partner for Nasal Sprays) | Renaissance Lakewood LLC
DBMR was attentive and engaged while discussing the Global Nasal Spray Market. They understood what we were looking for and was able to provide some examples from the report as requested. DBMR Service team has been responsive as needed. Depending on what my colleagues were looking for, I will recommend your services and would be happy to stay connected in case we can utilize your research in the future.
Business Intelligence and Analytics,
Ipsen Biopharm Limited
We are impressed by the CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT report - so a BIG thanks to you colleagues.
Competition Analyst,
Basler Web
I just wanted to share a quick note and let you know that you guys did a really good job. I’m glad I decided to work with you. I shall continue being associated with your company as long as we have market intelligence needs.
Marketing Director,
Buhler Group
It was indeed a good experience, would definitely recommend and come back for future prospects.
COO,
A global leader providing Drug Delivery Services
DBMR did an outstanding job on the Global Drug Delivery project, We were extremely impressed by the simple but comprehensive presentation of the study and the quality of work done. This report really helped us to access untapped opportunities across the globe.
Marketing Director,
Philips Healthcare
The study was customized to our targets and needs with well-defined milestones. We were impressed by the in-depth customization and inclusion of not only major but also minor players across the globe. The DBMR Market position grid helped us to analyze the market in different dimension which was very helpful for the team to get into the minute details.
Product manager,
Fujifilms
Thankful to the team for the amazing coordination, and helping me at the last moment with my presentation. It was indeed a comprehensive report that gave us revenue impacting solution enabling us to plan the right move.
Investor relations,
GE Healthcare
Thank you for the report, and addressing our needs in such short time. DBMR has outdone themselves in this project with such short timeframe.
Market Analyst,
Medincell
We found the results of this study compelling and will help our organization validate a market we are considering to enter. Thank you for a job well done.
Andrew - Senior Global Marketing Manager,
Medtronic (US)
I want to thank you for your help with this report – It’s been very helpful in our business planning and it well organized.
Amarildo - Manager, Global Strategic Alignment
MasterCard
We believe the work done by Data Bridge Team for our requirements in the North America Loyalty Management Market was fantastic and would love to continue working with your team moving forward.
Tor Hammer
Green Nexus LLc
Thank you for your quick response to this unfortunate circumstance. Please extend my thanks to your reach team. I will be contacting you in the future with further projects
I acknowledge the difficulty given by the very short warning for this report, and I think that its quality and your delivering time have been very satisfying.
Obviously, as a provider Data Bridge Market Research will be considered as a plus for future needs of Nippon Gases.
Yuki Kopyl (Asian Business Development Department)
UENO FOOD TECHNO INDUSTRY, LTD. (JAPAN)
Xylose report was very useful for our team. Thank you very much & hope to work with you again in the future